文献速递神经肿瘤

肿瘤电场治疗脑干胶质瘤的可行性模拟评估

Feasibility evaluation of tumor treating fields for brainstem gliomas.
PubMed 文献 · J Neurooncol · 2026-07-06

本研究利用7例脑干胶质瘤患者的MRI和CT进行患者特异性TTFields规划模拟,比较优化布局与标准布局的电场剂量。结果显示优化布局在各区域的局部最小场强均显著高于标准布局,且均达到或超过1.0 V/cm的治疗参考值,支持对幕下肿瘤开展前瞻性临床评估。

要点

  • 患者特异性建模可优化头皮阵列布局,提升脑干胶质瘤TTFields剂量。
  • 优化后各区域局部最小场强均≥1.0 V/cm治疗参考值。
  • 结果支持对幕下肿瘤开展前瞻性临床评估。

核心结论

  • 患者特异性建模可在脑干胶质瘤中利用头皮阵列实现有利的TTFields强度。
  • 研究结果支持对幕下肿瘤进行前瞻性临床评估。

研究设计与样本

  • 模拟研究,使用7例脑干胶质瘤患者的MRI和CT进行TTFields规划。
  • 采用MAXPOINT®平台优化头皮阵列布局,并行有限元计算。
  • 临床靶区定义为T1增强肿瘤加3 mm瘤周扩展。

主要发现

  • 优化布局的局部最小场强在所有区域均显著高于标准布局(所有p≤0.019)。
  • GTV中位局部最小场强为1.1 vs. 1.0 V/cm(p=0.019)。
  • CTV中位局部最小场强为1.1 vs. 1.0 V/cm(p=0.002)。
  • 脑干中位局部最小场强为1.3 vs. 1.1 V/cm(p=0.002)。
  • 后颅窝差异最大:中位局部最小场强1.5 vs. 1.2 V/cm(p<0.001)。

关键数值与推荐

  • 以局部最小场强≥1.0 V/cm作为治疗参考值。
  • 优化后所有局部最小场强值均达到或超过该参考值。

临床怎么用

  • 提示头皮阵列TTFields在脑干胶质瘤中可能达到治疗性剂量。
  • 为幕下肿瘤的前瞻性临床研究提供剂量学依据。

局限性

  • 本研究为模拟研究,样本量仅7例。
  • feasibility结论尚需前瞻性临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor treating fields (TTFields) are FDA-approved for supratentorial glioblastoma, but feasibility in infratentorial tumors remains poorly defined. This simulation study evaluated TTFields dose in brainstem gliomas using patient-specific modeling with scalp-only transducer arrays. METHODS: MRI and CT imaging from seven patients with brainstem gliomas were used for TTFields planning with MAXPOINT® (Novocure, Switzerland). Clinical target volume (CTV) was defined as enhancing tumor on T1 post-contrast MRI (Gross tumor volume, GTV) plus a 3 mm peritumoral expansion. The platform optimized scalp-only array layouts, and finite element calculations generated maps of local minimum field intensity (LMiFI, V/cm) and local minimum power density (LMiPD, mW/cm³). Values were compared against a standard, unplanned layout using one-sided paired t-tests, with LMiFI ≥ 1.0 V/cm as a therapeutic reference. RESULTS: MAXPOINT-optimized layouts achieved significantly higher LMiFI than the standard layout across all regions (all p ≤ 0.019). GTV median LMiFI was 1.1 vs. 1.0 V/cm (p = 0.019). CTV median LMiFI was 1.1 vs. 1.0 V/cm (p = 0.002). Brainstem median LMiFI was 1.3 vs. 1.1 V/cm (p = 0.002). Posterior fossa showed the largest difference: median LMiFI 1.5 vs. 1.2 V/cm (p < 0.001). All optimized LMiFI values met or exceeded the therapeutic reference. LMiPD was also significantly higher with MAXPOINT® across all regions (all p ≤ 0.006). CONCLUSION: This simulation study demonstrates that patient-specific modeling can achieve favorable TTFields intensities in brainstem gliomas using scalp-only arrays, supporting prospective clinical evaluation for infratentorial tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Chen AY, Shah R, Shi W, et al. Feasibility evaluation of tumor treating fields for brainstem gliomas. J Neurooncol. 2026. PMID: 42406140. doi:10.1007/s11060-026-05697-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。